474 related articles for article (PubMed ID: 25865648)
1. Allogeneic Hematopoietic Stem Cell Transplantation Is an Effective Salvage Therapy for Patients with Chronic Myeloid Leukemia Presenting with Advanced Disease or Failing Treatment with Tyrosine Kinase Inhibitors.
Nair AP; Barnett MJ; Broady RC; Hogge DE; Song KW; Toze CL; Nantel SH; Power MM; Sutherland HJ; Nevill TJ; Abou Mourad Y; Narayanan S; Gerrie AS; Forrest DL
Biol Blood Marrow Transplant; 2015 Aug; 21(8):1437-44. PubMed ID: 25865648
[TBL] [Abstract][Full Text] [Related]
2. Response to tyrosine kinase inhibitor therapy in patients with chronic myelogenous leukemia relapsing in chronic and advanced phase following allogeneic hematopoietic stem cell transplantation.
Wright MP; Shepherd JD; Barnett MJ; Nantel SH; Sutherland HJ; Toze CL; Hogge DE; Nevill TJ; Song KW; Abou Mourad YR; Narayanan S; Power MM; Smith CA; Forrest DL
Biol Blood Marrow Transplant; 2010 May; 16(5):639-46. PubMed ID: 20005967
[TBL] [Abstract][Full Text] [Related]
3. Allogeneic Transplantation in Chronic Myeloid Leukemia and the Effect of Tyrosine Kinase Inhibitors on Survival: A Quasi-Experimental Study.
Özen M; Üstün C; Öztürk B; Topçuoğlu P; Arat M; Gündüz M; Atilla E; Bolat G; Arslan Ö; Demirer T; Akan H; İlhan O; Beksaç M; Gürman G; Özcan M
Turk J Haematol; 2017 Mar; 34(1):16-26. PubMed ID: 27094579
[TBL] [Abstract][Full Text] [Related]
4. Superiority of allogeneic hematopoietic stem cell transplantation to nilotinib and dasatinib for adult patients with chronic myelogenous leukemia in the accelerated phase.
Xu L; Zhu H; Hu J; Wu D; Jiang H; Jiang Q; Huang X
Front Med; 2015 Sep; 9(3):304-11. PubMed ID: 26100855
[TBL] [Abstract][Full Text] [Related]
5. Retrospective Study of Allogeneic Hematopoietic Stem Cell Transplantation in Philadelphia Chromosome-Positive Leukemia: 25 Years' Experience at Gustave Roussy Cancer Campus.
Chamseddine AN; Willekens C; De Botton S; Bourhis JH
Clin Lymphoma Myeloma Leuk; 2015 Jun; 15 Suppl():S129-40. PubMed ID: 26297265
[TBL] [Abstract][Full Text] [Related]
6. Prognostic Factors for Outcomes of Allogeneic HSCT for Children and Adolescents/Young Adults With CML in the TKI Era.
Shimada H; Tanizawa A; Kondo T; Nagamura-Inoue T; Yasui M; Tojo A; Muramatsu H; Eto T; Doki N; Tanaka M; Sato M; Noguchi M; Uchida N; Takahashi Y; Sakata N; Ichinohe T; Hashii Y; Kato K; Atsuta Y; Ohashi K;
Transplant Cell Ther; 2022 Jul; 28(7):376-389. PubMed ID: 35447373
[TBL] [Abstract][Full Text] [Related]
7. Transplant to treatment-free remission: the evolving view of 'cure' in chronic myeloid leukemia.
Yong AS; Brissot E; Rubinstein S; Savani BN; Mohty M
Expert Rev Hematol; 2015 Dec; 8(6):785-97. PubMed ID: 26364871
[TBL] [Abstract][Full Text] [Related]
8. Reduced-intensity allogeneic hematopoietic stem cell transplantation combined with imatinib has comparable event-free survival and overall survival to long-term imatinib treatment in young patients with chronic myeloid leukemia.
Zhao Y; Wang J; Luo Y; Shi J; Zheng W; Tan Y; Cai Z; Huang H
Ann Hematol; 2017 Aug; 96(8):1353-1360. PubMed ID: 28624905
[TBL] [Abstract][Full Text] [Related]
9. Imatinib Mesylate Versus Allogeneic Hematopoietic Stem Cell Transplantation for Patients with Chronic Myelogenous Leukemia.
Zhang GF; Zhou M; Bao XB; Qiu HY; Li Z; Xue SL
Asian Pac J Cancer Prev; 2016; 17(9):4477-4481. PubMed ID: 27797264
[TBL] [Abstract][Full Text] [Related]
10. Patients with Philadelphia-positive leukemia with BCR-ABL kinase mutations before allogeneic transplantation predominantly relapse with the same mutation.
Egan DN; Beppu L; Radich JP
Biol Blood Marrow Transplant; 2015 Jan; 21(1):184-9. PubMed ID: 25300870
[TBL] [Abstract][Full Text] [Related]
11. [Outcomes of imatinib and allogeneic hematopoietic stem cell transplantation in the treatment of chronic myeloid leukemia].
Zhou M; Sha X; Qiu H; He G; Xu Y; Cen J; Pan J; Chen S; Sun A; Zhang R; Wu D
Zhonghua Xue Ye Xue Za Zhi; 2014 Feb; 35(2):126-8. PubMed ID: 24606653
[TBL] [Abstract][Full Text] [Related]
12. A comparison of long-term outcomes of donor lymphocyte infusions and tyrosine kinase inhibitors in patients with relapsed CML after allogeneic hematopoietic cell transplantation.
Shanavas M; Messner HA; Kamel-Reid S; Atenafu EG; Gupta V; Kuruvilla J; Kim DD; Uhm J; Lambie A; Ellis L; Lipton JH
Clin Lymphoma Myeloma Leuk; 2014 Feb; 14(1):87-92. PubMed ID: 24252361
[TBL] [Abstract][Full Text] [Related]
13. Allogeneic hematopoietic SCT in combination with tyrosine kinase inhibitor treatment compared with TKI treatment alone in CML blast crisis.
Jiang H; Xu LP; Liu DH; Liu KY; Chen SS; Jiang B; Jiang Q; Chen H; Chen YH; Han W; Zhang XH; Wang Y; Wang JZ; Wang FR; Qin YZ; Lai YY; Huang XJ
Bone Marrow Transplant; 2014 Sep; 49(9):1146-54. PubMed ID: 25046218
[TBL] [Abstract][Full Text] [Related]
14. Cytomegalovirus Reactivation after Allogeneic Hematopoietic Stem Cell Transplantation is Associated with a Reduced Risk of Relapse in Patients with Acute Myeloid Leukemia Who Survived to Day 100 after Transplantation: The Japan Society for Hematopoietic Cell Transplantation Transplantation-related Complication Working Group.
Takenaka K; Nishida T; Asano-Mori Y; Oshima K; Ohashi K; Mori T; Kanamori H; Miyamura K; Kato C; Kobayashi N; Uchida N; Nakamae H; Ichinohe T; Morishima Y; Suzuki R; Yamaguchi T; Fukuda T
Biol Blood Marrow Transplant; 2015 Nov; 21(11):2008-16. PubMed ID: 26211985
[TBL] [Abstract][Full Text] [Related]
15. Improved outcome in patients with chronic myelogenous leukemia after allogeneic hematopoietic stem cell transplantation over the past 25 years: a single-center experience.
Boehm A; Walcherberger B; Sperr WR; Wöhrer S; Dieckmann K; Rosenmayr A; Pernicka E; Fischer G; Worel N; Mitterbauer G; Schwarzinger I; Mitterbauer M; Haas OA; Lechner K; Hinterberger W; Valent P; Greinix HT; Rabitsch W; Kalhs P
Biol Blood Marrow Transplant; 2011 Jan; 17(1):133-40. PubMed ID: 20601032
[TBL] [Abstract][Full Text] [Related]
16. Chronic myeloid leukemia-transplantation in the tyrosine kinase era.
Innes AJ; Apperley JF
Hematol Oncol Clin North Am; 2014 Dec; 28(6):1037-53. PubMed ID: 25459178
[TBL] [Abstract][Full Text] [Related]
17. Prognostic factors for outcomes of allogeneic stem cell transplantation in chronic phase chronic myeloid leukemia in the era of tyrosine kinase inhibitors.
Lee SE; Choi SY; Kim SH; Jang EJ; Bang JH; Byeun JY; Park JE; Jeon HR; Oh YJ; Yahng SA; Cho BS; Eom KS; Kim YJ; Lee S; Min CK; Kim HJ; Lee JW; Min WS; Park CW; Kim DW
Hematology; 2014 Mar; 19(2):63-72. PubMed ID: 23684143
[TBL] [Abstract][Full Text] [Related]
18. Individualized intervention guided by BCR-ABL transcript levels after HLA-identical sibling donor transplantation improves HSCT outcomes for patients with chronic myeloid leukemia.
Huang XJ; Xu LP; Liu KY; Liu DH; Chen H; Liu YR; Chen YH; Han W; Wang Y
Biol Blood Marrow Transplant; 2011 May; 17(5):649-56. PubMed ID: 20691800
[TBL] [Abstract][Full Text] [Related]
19. HLA-mismatched/haploidentical hematopoietic stem cell transplantation without in vitro T cell depletion for chronic myeloid leukemia: improved outcomes in patients in accelerated phase and blast crisis phase.
Xiao-Jun H; Lan-Ping X; Kai-Yan L; Dai-Hong L; Huan C; Wei H; Yu-Hong C; Jing-Zhi W; Yao C; Xiao-Hui Z; Hong-Xia S; Dao-Pei L
Ann Med; 2008; 40(6):444-55. PubMed ID: 18608121
[TBL] [Abstract][Full Text] [Related]
20. Comparable Outcomes of Pre- Versus Post-Tyrosine Kinase Inhibitor Era Treatment in Chronic Myeloid Leukemia: A Retrospective Cohort Study With Long-term Follow-up.
Tavakoli S; Khalaj F; Kasaeian A; Mousavi SA; Mousavian AH; Arabi F; Rad S; Rostami S; Barkhordar M; Biglari M; Mardani-Fard HA; Alemi H; Khavandgar N; Kamranzadeh Fumani H; Janbabai G; Mousavi SA; Ghavamzadeh A; Vaezi M
Cell Transplant; 2023; 32():9636897231163212. PubMed ID: 37013251
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
